Interestingly, LCN2 has also been correlated with disease advancement [9] and appears to modulate several pathways such as the ERK/slug pathway in prostate cancer [10] and the Met/FAK pathway in liver cancer [11] to contribute to EMT progression. This evidence concerns the gene LCN2 and prostate carcinoma.